Drug intelligence / Profile preview

NAV3-32

Development stage: Preclinical
Lead developer: Navidea Biopharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NAV3-32 is a drug candidate developed by Navidea Biopharmaceuticals. It is part of the company's Manocept platform, which is designed to target the CD206 mannose receptor found on activated macrophages. Navidea is currently advancing NAV3-32 through clinical trials, with funding secured to support its development.

Beyond the preview

Go deeper on NAV3-32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAV3-32.

Explore the full profile